Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526111 | 0.85 | POLB (0.60) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL27802960 | 0.81 | SMN1; SMN2 (0.64) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL1231252 | 0.77 | POLB (0.61) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL83922 | 0.76 | HPGD (0.86) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL11055288 | 0.76 | HPGD (0.54) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL7400924 | 0.76 | HPGD (0.54) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL4903379 | 0.75 | POLB (0.75) | POLBALDH1A1LMNAHPGDGAA | |
| Hydrochloric Acid SCHEMBL7397125 | 0.74 | HPGD (0.53) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL473071 | 0.74 | HPGD (0.53) | POLBALDH1A1LMNAHPGDGAA | |
| SCHEMBL1647857 | 0.74 | ALDH1A1 (0.69) | POLBALDH1A1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751123-B1 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS (JP) | 2000-05-10 | — | — | EP | claimed |
| US-5744609-A | REACTING AN ALKYLTHIOBENZAMIDE WITH A HALOGEN IN A HETEROGENOUS SOLVENT TO GIVE ALKYLSULFURYLBENZAMIDES INTERMEDIATES; USEFUL ANTIBACTERIAL AND ANTIFUNGAL AGENT | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1998-04-28 | — | — | US | claimed |
| US-5672751-A | TREATMENT OF A HALOBENZAMIDE WITH AN ALKANETHIOL IN THE PRESENCE OF A PHASE TRANSFER CATALYST | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-09-30 | — | — | US | claimed |
| EP-0751123-A2 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-01-02 | — | — | EP | claimed |
| EP-0657438-A2 | Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1995-06-14 | — | — | EP | claimed |
| JP-7145143-A | — | — | None | — | — | JP | disclosed |
| CN-117304132-B | Synthesis method of visible light-promoted selenothiazolin compound | 南通大学 | 2024-12-06 | — | — | CN | disclosed |
| CN-117304132-A | Synthesis method of visible light-promoted selenothiazolin compound | 南通大学 | 2023-12-29 | — | — | CN | disclosed |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7880012-B2 | e.g. 3-[2-(3-Isopropoxy-5-phenoxy-benzoylamino)-thiazol-5-yl-sulfanyl]-propionic acid methyl ester; metabolic disorder, blood glucose lowering, hyperglycemia, impaired glucose tolerance (IGT), Syndrome X, Polycystic Ovarian Syndrome, type I and type II diabetes, dyslipidemia, hyperlipidemia etc. | TRANSTECH PHARMA, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, LLC | 2009-07-09 | — | — | US | disclosed |
| EP-2019824-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-0751123-A2 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-01-02 | — | — | EP | disclosed |
| EP-0751123-A2 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-5508416-A | HALOGENATING A 2-(ALKYLTHIO)BENZAMIDE, CYCLIZATION TO HETERO RING AND N-S LINKAGE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5508416-A | HALOGENATING A 2-(ALKYLTHIO)BENZAMIDE, CYCLIZATION TO HETERO RING AND N-S LINKAGE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| CN-1107837-A | Process for producing alkylsulfinylbenzamides and 1, 2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS (JP) | 1995-09-06 | — | — | CN | disclosed |
| EP-0657438-A2 | Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1995-06-14 | — | — | EP | disclosed |
| EP-0657438-A2 | Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1995-06-14 | — | — | EP | disclosed |
| JP-H07145143-A | PRODUCTION OF ALKYLSULFINYLBENZAMIDES | SUMITOMO SEIKA CHEM CO LTD | 1995-06-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | POLB 2924/4885ALDH1A1 1394/4885LMNA 3482/4885 |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | POLB 2924/4885ALDH1A1 1394/4885LMNA 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.